---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-007944"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:39:59.238996+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage

## Summary
- Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.
- Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.
- Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.
- Plan substantially complete by end of Q2 2025.

## SEC filing metadata
- accession: 0001641172-25-007944
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000164117225007944/0001641172-25-007944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000164117225007944/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-007944
- JSON: https://secwatch.observer/filing/0001641172-25-007944.json
- Plain text: https://secwatch.observer/filing/0001641172-25-007944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.